Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Research

PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients

Authors: Ming Li, Shanhu Li, Biao Liu, Meng-Meng Gu, Shitao Zou, Bei-Bei Xiao, Lan Yu, Wei-Qun Ding, Ping-Kun Zhou, Jundong Zhou, Zeng-Fu Shang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Background

Non-small cell lung cancer (NSCLC) is the most commonly diagnosed type of lung cancer that is associated with poor prognosis. In this study we explored the potential role of p53-induced gene 3 (PIG3) in the progression of NSCLC.

Methods

Immunohistochemistry was used to determine the expression levels of PIG3 in 201 NSCLC patients. We performed in vitro studies and silenced endogenous PIG3 by using specific siRNAs that specific target PIG3. Immunofluorescent staining was performed to determine the effect of PIG3 on mitotic progression in NSCLC cells. The growth rates of microtubules were determined by microtubule nucleation analysis. Cell proliferation and chemosensitivity were analyzed by CCK8 assays. Annexin V staining and β-galactosidase activity analysis were used to evaluate PIG3 deficiency-related apoptosis and senescence, respectively.

Results

PIG3 expression levels negatively correlated with overall survival and disease-free survival of NSCLC patients. Knock down of PIG3 resulted in repressed proliferation of NSCLC cells and increased aberrant mitosis, which included misaligning and lagging chromosomes, and bi- or multi-nucleated giant cells. In addition, PIG3 contributed to mitotic spindle assembly by promoting microtubule growth. Furthermore, loss of PIG3 sensitized NSCLC cells to docetaxel by enhancing docetaxel-induced apoptosis and senescence.

Conclusions

Our results indicate that PIG3 promotes NSCLC progression and therefore suggest that PIG3 may be a potential prognostic biomarker and novel therapeutic target for the treatment of NSCLC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840–50.CrossRefPubMed
3.
4.
Seo AN, Yang JM, Kim H, Jheon S, Kim K, Lee CT, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014;110:2688–99.CrossRefPubMedPubMedCentral
5.
Rooney C, Sethi T. Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer. Chest. 2015;148:1063–72.CrossRefPubMed
6.
Rosell R, Karachaliou N. Lung cancer in 2014: optimizing lung cancer treatment approaches. Nat Rev Clin Oncol. 2015;12:75–6.CrossRefPubMed
7.
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300–5.CrossRefPubMed
8.
Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006;16:55–65.CrossRefPubMedPubMedCentral
9.
Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet. 2002;30:315–20.CrossRefPubMed
10.
Guan X, Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q. Functional repeats (TGYCC)n in the p53-inducible gene 3 (PIG3) promoter and susceptibility to squamous cell carcinoma of the head and neck. Carcinogenesis. 2013;34:812–7.CrossRefPubMed
11.
Porte S, Valencia E, Yakovtseva EA, Borras E, Shafqat N, Debreczeny JE, et al. Three-dimensional structure and enzymatic function of proapoptotic human p53-inducible quinone oxidoreductase PIG3. J Biol Chem. 2009;284:17194–205.CrossRefPubMedPubMedCentral
12.
Kang MY, Kim HB, Piao C, Lee KH, Hyun JW, Chang IY, et al. The critical role of catalase in prooxidant and antioxidant function of p53. Cell Death Differ. 2013;20:117–29.CrossRefPubMed
13.
Lee JH, Kang Y, Khare V, Jin ZY, Kang MY, Yoon Y, et al. The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage. Oncogene. 2010;29(10):1431–50.CrossRefPubMed
14.
Li B, Shang ZF, Yin JJ, Xu QZ, Liu XD, Wang Y, et al. PIG3 functions in DNA damage response through regulating DNA-PKcs homeostasis. Int J Biol Sci. 2013;9:425–34.CrossRefPubMedPubMedCentral
15.
16.
Chen G, Xu JY, Chen J, Zhang JX, Zhou J, Liang Y, et al. Loss of PIG3 increases HIF-1alpha level by promoting protein synthesis via mTOR pathway in renal cell carcinoma cells. Oncotarget. 2016;7:27176–84.PubMedPubMedCentral
17.
Xu J, Cai J, Jin X, Yang J, Shen Q, Ding X, et al. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway. Oncol Rep. 2015;34:1424–30.PubMed
18.
Zhao J, Kim JE, Reed E, Li QQ. Molecular mechanism of antitumor activity of taxanes in lung cancer. Int J Oncol. 2005;27:247–56.PubMed
19.
Li M, Ma Y, Huang P, Du A, Yang X, Zhang S, et al. Lentiviral DDX46 knockdown inhibits growth and induces apoptosis in human colorectal cancer cells. Gene. 2015;560:237–44.CrossRefPubMed
20.
Chen P, Zhu J, Liu DY, Li HY, Xu N, Hou M. Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med Oncol. 2014;31:775.CrossRefPubMed
21.
Shang Z, Yu L, Lin YF, Matsunaga S, Shen CY, Chen BP. DNA-PKcs activates the Chk2-Brca1 pathway during mitosis to ensure chromosomal stability. Oncogenesis. 2014;3:e85.CrossRefPubMedPubMedCentral
22.
Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev. 2007;17:157–62.CrossRefPubMed
23.
Mason PJ, Bessler M. Cytokinesis failure and attenuation: new findings in Fanconi anemia. J Clin Invest. 2011;121:27–30.CrossRefPubMed
24.
Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397–408.CrossRefPubMed
25.
Rao CV, Yamada HY, Yao Y, Dai W. Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis. 2009;30:1469–74.CrossRefPubMedPubMedCentral
26.
27.
Kotsinas A, Aggarwal V, Tan EJ, Levy B, Gorgoulis VG. PIG3: a novel link between oxidative stress and DNA damage response in cancer. Cancer Lett. 2012;327:97–102.CrossRefPubMed
28.
Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005;24:287–91.CrossRefPubMed
29.
Gavriilidis P, Giakoustidis A, Giakoustidis D. Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review. J Clin Med Res. 2015;7:742–51.CrossRefPubMedPubMedCentral
30.
Shang ZF, Yu L, Li B, Tu WZ, Wang Y, Liu XD, et al. 4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1. Cell Cycle. 2012;11:3463–71.CrossRefPubMedPubMedCentral
31.
Shang ZF, Huang B, Xu QZ, Zhang SM, Fan R, Liu XD, et al. Inactivation of DNA-dependent protein kinase leads to spindle disruption and mitotic catastrophe with attenuated checkpoint protein 2 Phosphorylation in response to DNA damage. Cancer Res. 2010;70:3657–66.CrossRefPubMed
32.
Lee KJ, Lin YF, Chou HY, Yajima H, Fattah KR, Lee SC, et al. Involvement of DNA-dependent protein kinase in normal cell cycle progression through mitosis. J Biol Chem. 2011;286:12796–802.CrossRefPubMedPubMedCentral
33.
Douglas P, Ye R, Trinkle-Mulcahy L, Neal JA, De Wever V, Morrice NA, et al. Polo-like kinase 1 (PLK1) and protein phosphatase 6 (PP6) regulate DNA-dependent protein kinase catalytic subunit (DNA-PKcs) phosphorylation in mitosis. Biosci Rep. 2014;34:e00113.CrossRefPubMedPubMedCentral
34.
Lee KJ, Shang ZF, Lin YF, Sun J, Morotomi-Yano K, Saha D, et al. The Catalytic Subunit of DNA-Dependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry. Neoplasia. 2015;17:329–38.CrossRefPubMedPubMedCentral
35.
Huang B, Shang ZF, Li B, Wang Y, Liu XD, Zhang SM, et al. DNA-PKcs associates with PLK1 and is involved in proper chromosome segregation and cytokinesis. J Cell Biochem. 2014;115:1077–88.CrossRefPubMed
36.
Yu L, Shang ZF, Hsu FM, Zhang Z, Tumati V, Lin YF, et al. NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor. Oncotarget. 2015;6:3848–60.CrossRefPubMedPubMedCentral
37.
Ertych N, Stolz A, Stenzinger A, Weichert W, Kaulfuss S, Burfeind P, et al. Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nat Cell Biol. 2014;16:779–91.CrossRefPubMedPubMedCentral
38.
Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih Ie M, Vogelstein B, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A. 2002;99:16226–31.CrossRefPubMedPubMedCentral
39.
Testa JR, Liu Z, Feder M, Bell DW, Balsara B, Cheng JQ, et al. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet. 1997;95:20–32.CrossRefPubMed
40.
Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A, et al. Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res. 2003;9:2294–9.PubMed
41.
42.
Park MT, Oh ET, Song MJ, Lee H, Choi EK, Park HJ. NQO1 prevents radiation-induced aneuploidy by interacting with Aurora-A. Carcinogenesis. 2013;34:2470–85.CrossRefPubMed
43.
Janne PA, Smith I, McWalter G, Mann H, Dougherty B, Walker J, et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Br J Cancer. 2015;113:199–203.CrossRefPubMedPubMedCentral
44.
45.
Brodie SA, Li G, Harvey D, Khuri FR, Vertino PM, Brandes JC. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. Oncotarget. 2015;6:30773–86.PubMedPubMedCentral
Metadata
Title
PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients
Authors
Ming Li
Shanhu Li
Biao Liu
Meng-Meng Gu
Shitao Zou
Bei-Bei Xiao
Lan Yu
Wei-Qun Ding
Ping-Kun Zhou
Jundong Zhou
Zeng-Fu Shang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0508-2

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue

Research

Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer

Research

Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism

Research

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53

Research

Doxorubicin combined with low intensity ultrasound suppresses the growth of oral squamous cell carcinoma in culture and in xenografts

Research

Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma

Research

Exosomes isolated from cancer patients’ sera transfer malignant traits and confer the same phenotype of primary tumors to oncosuppressor-mutated cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits